175 related articles for article (PubMed ID: 22235075)
1. Expert panel advocates surveillance for men with low-risk prostate cancer.
Slomski A
JAMA; 2012 Jan; 307(2):133. PubMed ID: 22235075
[No Abstract] [Full Text] [Related]
2. Prostate cancer: to treat or not to treat?
Johns Hopkins Med Lett Health After 50; 2013 Jan; 24(12):1-2. PubMed ID: 24000432
[No Abstract] [Full Text] [Related]
3. Prostate Cancer in Elderly Men: Screening, Active Surveillance, and Definitive Therapy.
Roussel B; Ouellet GM; Mohile SG; Dale W
Clin Geriatr Med; 2015 Nov; 31(4):615-29. PubMed ID: 26476120
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance for prostate cancer.
Thompson IM; Klotz L
JAMA; 2010 Dec; 304(21):2411-2. PubMed ID: 21119090
[No Abstract] [Full Text] [Related]
5. Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
Mallapareddi A; Ruterbusch J; Reamer E; Eggly S; Xu J
Fam Pract; 2017 Feb; 34(1):90-97. PubMed ID: 28034917
[TBL] [Abstract][Full Text] [Related]
6. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
7. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
8. Low-risk prostate cancer patient: active treatment.
Moul JW; Saad F
Can J Urol; 2005 Jun; 12 Suppl 2():25-7. PubMed ID: 16018829
[TBL] [Abstract][Full Text] [Related]
9. [-2]pro-prostate specific antigen as an aid in prostate biopsy.
Bangma C
J Urol; 2012 Oct; 188(4):1070-1. PubMed ID: 22901580
[No Abstract] [Full Text] [Related]
10. Watchful waiting for prostate cancer: a review article.
Chodak GW; Warren KS
Prostate Cancer Prostatic Dis; 2006; 9(1):25-9. PubMed ID: 16402090
[TBL] [Abstract][Full Text] [Related]
11. Re: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Taneja SS
J Urol; 2015 Jan; 193(1):128-9. PubMed ID: 25523659
[No Abstract] [Full Text] [Related]
12. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
Markun S
Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
[No Abstract] [Full Text] [Related]
13. The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?
Reis LO; Carter HB
Int Braz J Urol; 2015; 41(1):10-4. PubMed ID: 25928505
[No Abstract] [Full Text] [Related]
14. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
[TBL] [Abstract][Full Text] [Related]
15. Expectant management of localized prostate cancer--who, what, when, where and how?
Ehdaie B
J Urol; 2012 Sep; 188(3):696-7. PubMed ID: 22818346
[No Abstract] [Full Text] [Related]
16. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Tosoian JJ; Trock BJ; Landis P; Feng Z; Epstein JI; Partin AW; Walsh PC; Carter HB
J Clin Oncol; 2011 Jun; 29(16):2185-90. PubMed ID: 21464416
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
18. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
19. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options.
Bayliss D; Duff J; Stricker P; Walker K
Urol Nurs; 2016; 36(3):141-9. PubMed ID: 27501595
[TBL] [Abstract][Full Text] [Related]
20. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
